The following was published on 

Rapid and dramatic improvement in thyroid eye disease (TED) occurred in more than 80% of patients treated with a biologic targeting insulin-like growth factor (IGF)-1 receptor, a phase III trial showed.

Overall, 82.9% of patients had at least a 2-mm reduction in proptosis at 24 weeks with teprotumumab as compared with fewer than 10% of patients randomized to placebo. Almost 80% of teprotumumab-treated patients met the dual outcomes of proptosis reduction plus improvement in Clinical Activity Score (CAS).

The anti-IGF-1R antibody was generally well tolerated, as the most common adverse event was muscle spasm, and fewer than 5% of patients treated with teprotumumab discontinued because of adverse events, as reported here at the American Academy of Ophthalmology meeting.

Click here to read the full article.